Comparative Pharmacology
Head-to-head clinical analysis: FLUOXYMESTERONE versus TESULOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOXYMESTERONE versus TESULOID.
FLUOXYMESTERONE vs TESULOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic androgen receptor agonist; binds to androgen receptors, modulating gene expression and promoting protein synthesis, muscle growth, and secondary sexual characteristic development.
Tesuloid is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), thereby reducing pro-inflammatory cytokine production and immune-mediated inflammation.
Adults: 5-20 mg orally once daily. For replacement therapy, 5-10 mg daily; for hypogonadism, 5-20 mg daily for several months.
Intravenous infusion of 500 mg over 60 minutes every 2 weeks.
None Documented
None Documented
Terminal elimination half-life: 9.2 hours; clinical context: supports once-daily dosing for androgen replacement, with steady-state achieved in ~2 days
Clinical Note
moderateAcarbose + Fluoxymesterone
"Acarbose may increase the hypoglycemic activities of Fluoxymesterone."
Clinical Note
moderateSunitinib + Fluoxymesterone
"Sunitinib may increase the hypoglycemic activities of Fluoxymesterone."
Clinical Note
moderatePrednisolone + Fluoxymesterone
"Prednisolone may increase the fluid retaining activities of Fluoxymesterone."
Clinical Note
moderateDexamethasone + Fluoxymesterone
16–20 hours in healthy adults; prolonged to 30–40 hours in moderate renal impairment (CrCl <50 mL/min); clinically significant accumulation risk in renal disease.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%
Primarily renal excretion (85% unchanged, 10% as glucuronide conjugate); 5% fecal.
Category C
Category C
Androgen
Androgen
"Dexamethasone may increase the fluid retaining activities of Fluoxymesterone."